PFPaula Fernandez

Paula Fernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paula Fernandez has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    by Sergio Matarraz, Pilar Leoz, Ana Yeguas-Bermejo, Vincent van der Velden, Anne E. Bras, Jose I. Sánchez Gallego, Quentin Lecrevisse, Rosa Ayala-Bueno, Cristina Teodosio, Ignacio Criado, et al.


  • Open Access

    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

    by Anne E. Bras, Zgjim Osmani, Valerie de Haas, Mojca Jongen‐Lavrencic, Jeroen G. Te Marvelde, C. Michel Zwaan, Ester Mejstrikova, Paula Fernandez, Tomasz Szczepanski, Alberto Orfao, et al.

    Summary: Given its myeloid‐restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte‐based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.


  • Open Access

    Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

    by L Lhermitte, E Mejstrikova, A J van der Sluijs-Gelling, G E Grigore, L Sedek, A E Bras, G Gaipa, E Sobral da Costa, M Novakova, E Sonneveld, et al.

    Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant classification panel (T-cell acute lymphoblastic leukemia (T-ALL), B-cell precursor (BCP)-ALL and/or acute myeloid leukemia (AML)) and final diagnosis. Now we built a reference database with 656 typical AL samples (145 T-ALL, 377 BCP-ALL, 134 AML), processed and analyzed via standardized protocols. Using principal component analysis (PCA)-based plots and automated classification algorithms for direct comparison of single-cells from individual patients against the database, another 783 cases were subsequently evaluated. Depending on the database-guided results, patients were categorized as: (i) typical T, B or Myeloid without or; (ii) with a transitional component to another lineage; (iii) atypical; or (iv) mixed-lineage. Using this automated algorithm, in 781/783 cases (99.7%) the right panel was selected, and data comparable to the final WHO-diagnosis was already provided in >93% of cases (85% T-ALL, 97% BCP-ALL, 95% AML and 87% mixed-phenotype AL patients), even without data on the full-characterization panels. Our results show that database-guided analysis facilitates standardized interpretation of ALOT results and allows accurate selection of the relevant classification panels, hence providing a solid basis for designing future WHO AL classifications.


  • Open Access

    Using Digital RNA Counting and Flow Cytometry to Compare mRNA with Protein Expression in Acute Leukemias

    by Paula Fernandez, Max Solenthaler, Olivier Spertini, Stephane Quarroz, Alicia Rovo, Pierre-Yves Lovey, Leda Leoncini, Sylvie Ruault-Jungblut, Mathilde D’aSaro, Olivier Schaad, et al.

    The diagnosis of malignant hematologic diseases has become increasingly complex during the last decade. It is based on the interpretation of results from different laboratory analyses, which range from microscopy to gene expression profiling. Recently, a method for the analysis of RNA phenotypes has been developed, the nCounter technology (Nanostring® Technologies), which allows for simultaneous quantification of hundreds of RNA molecules in biological samples. We evaluated this technique in a Swiss multi-center study on eighty-six samples from acute leukemia patients. mRNA and protein profiles were established for normal peripheral blood and bone marrow samples. Signal intensities of the various tested antigens with surface expression were similar to those found in previously performed Affymetrix microarray analyses. Acute leukemia samples were analyzed for a set of twenty-two validated antigens and the Pearson Correlation Coefficient for nCounter and flow cytometry results was calculated. Highly significant values between 0.40 and 0.97 were found for the twenty-two antigens tested. A second correlation analysis performed on a per sample basis resulted in concordant results between flow cytometry and nCounter in 44–100% of the antigens tested (mean = 76%), depending on the number of blasts present in a sample, the homogeneity of the blast population, and the type of leukemia (AML or ALL). The nCounter technology allows for fast and easy depiction of a mRNA profile from hematologic samples. This technology has the potential to become a valuable tool for the diagnosis of acute leukemias, in addition to multi-color flow cytometry.


  • Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma

    by M Heizmann, A C O'Meara, P R Moosmann, I A F M Heijnen, M Zuberbühler, P Fernandez, J Burger, A Huber, M Wernli, M J Bargetzi

    High-dose chemotherapy (HDT) and hematopoietic SCT are effective in patients with relapsing or refractory malignant lymphoma. Collection of sufficient numbers of stem cells is a prerequisite for such a therapy. In a pilot trial, we evaluated the feasibility of stem cell mobilization with vinorelbine/G-CSF in patients with lymphoma, a regimen allowing precise timing and harvesting of sufficient stem cells in myeloma patients. Forty-five patients with lymphoma received vinorelbine 35 mg/m2 i.v. on day 1 and G-CSF 10 μg/kg/day s.c., divided in two daily doses from day 4 until collection. Stem cell collection was successfully performed in 43 patients (96%) with a median of 3.6 × 106 CD34+ cells/kg (range: 1.4–16) in the collected product. In 28 patients (62%), the first stem cell apheresis was performed on day 8, and for 28 patients a sufficient stem cell yield was reached with one apheresis only. All 43 patients underwent high-dose chemotherapy with BEAM and auto-SCT with hematological recovery on time and without unexpected toxicity. In conclusion, vinorelbine/G-CSF allows accurate timing and safe harvesting of sufficient stem cells in patients with malignant lymphoma.


  • The IKK Inhibitor BMS-345541 Affects Multiple Mitotic Cell Cycle Transitions

    by Hana Blazkova, Conrad von Schubert, Keith Mikule, Rebekka Schwab, Nico Angliker, Jacqueline Schmuckli-Maurer, Paula C. Fernandez, Stephen Doxsey, Dirk A. Dobbelaere

    The IκB kinase (IKK) complex controls processes such as inflammation, immune responses, cell survival and the proliferation of both normal and tumor cells. By activating NFκB, the IKK c...


  • Open Access

    Werner syndrome protein limits MYC-induced cellular senescence

    by Carla Grandori, Kou-Juey Wu, Paula Fernandez, Celine Ngouenet, Jonathan Grim, Bruce E. Clurman, Michael J. Moser, Junko Oshima, David W. Russell, Karen Swisshelm, et al.

    The MYC oncoprotein is a transcription factor that coordinates cell growth and division. MYC overexpression exacerbates genomic instability and sensitizes cells to apoptotic stimuli. Here we demonstrate that MYC directly stimulates transcription of the human Werner syndrome gene,WRN, which encodes a conserved RecQ helicase. Loss-of-function mutations inWRNlead to genomic instability, an elevated cancer risk, and premature cellular senescence. The overexpression of MYC in WRN syndrome fibroblasts or after WRN depletion from control fibroblasts led to rapid cellular senescence that could not be suppressed byhTERTexpression. We propose thatWRNup-regulation by MYC may promote MYC-driven tumorigenesis by preventing cellular senescence.


  • Open Access

    MYC recruits the TIP60 histone acetyltransferase complex to chromatin

    by Scott R Frank, Tiziana Parisi, Stefan Taubert, Paula Fernandez, Miriam Fuchs, Ho‐Man Chan, David M Livingston, Bruno Amati

    The transcription factor MYC binds specific DNA sites in cellular chromatin and induces the acetylation of histones H3 and H4. However, the histone acetyltransferases (HATs) that are responsible for these modifications have not yet been identified. MYC associates with TRRAP, a subunit of distinct macromolecular complexes that contain the HATs GCN5/PCAF or TIP60. Although the association of MYC with GCN5 has been shown, its interaction with TIP60 has never been analysed. Here, we show that MYC associates with TIP60 and recruits it to chromatin in vivo with four other components of the TIP60 complex: TRRAP, p400, TIP48 and TIP49. Overexpression of enzymatically inactive TIP60 delays the MYC‐induced acetylation of histone H4, and also reduces the level of MYC binding to chromatin. Thus, the TIP60 HAT complex is recruited to MYC‐target genes and, probably with other other HATs, contributes to histone acetylation in response to mitogenic signals.


  • Top Cited Papers
    Open Access

    Genomic targets of the human c-Myc protein

    by Paula C. Fernandez, Scott R. Frank, Luquan Wang, Marianne Schroeder, Suxing Liu, Jonathan Greene, Andrea Cocito, Bruno Amati

    The transcription factor Myc is induced by mitogenic signals and regulates downstream cellular responses. If overexpressed, Myc promotes malignant transformation. Myc modulates expression of diverse genes in experimental systems, but few are proven direct targets. Here, we present a large-scale screen for genomic Myc-binding sites in live human cells. We used bioinformatics to select consensus DNA elements (CACGTG or E-boxes) situated in the 5′ regulatory region of genes and measured Myc binding to those sequences in vivo by quantitative chromatin immunoprecipitation. Strikingly, most promoter-associated E-boxes showed selective recovery with Myc, unlike non-E-box promoters or E-boxes in bulk genomic DNA. Promoter E-boxes were distributed in two groups bound by Myc at distinct frequencies. The high-affinity group included an estimated 11% of all cellular loci, was highly conserved among different cells, and was bound independently of Myc expression levels. Overexpressed Myc associated at increased frequency with low-affinity targets and, at extreme levels, also with other sequences, suggesting that some binding was not sequence-specific. The strongest DNA-sequence parameter defining high-affinity targets was the location of E-boxes within CpG islands, correlating with an open, preacetylated state of chromatin. Myc further enhanced histone acetylation, with or without accompanying induction of mRNA expression. Our findings point to a high regulatory and biological diversity among Myc-target genes.


  • Hijacking of Host Cell IKK Signalosomes by the Transforming Parasite Theileria

    by Volker T. Heussler, Sven Rottenberg, Rebekka Schwab, Peter KüeNzi, Paula C. Fernandez, Susan McKellar, Brian Shiels, Zhijian J. Chen, Kim Orth, David Wallach, et al.

    Parasites have evolved a plethora of mechanisms to ensure their propagation and evade antagonistic host responses. The intracellular protozoan parasite Theileria is the only eukaryote known to induce uncontrolled host cell proliferation. Survival of Theileria -transformed leukocytes depends strictly on constitutive nuclear factor kappa B (NF-κB) activity. We found that this was mediated by recruitment of the multisubunit IκB kinase (IKK) into large, activated foci on the parasite surface. IKK signalosome assembly was specific for the transforming schizont stage of the parasite and was down-regulated upon differentiation into the nontransforming merozoite stage. Our findings provide insights into IKK activation and how pathogens subvert host-cell signaling pathways.